SAN DIEGO, CA – [2025.11.17] – At the Society for Neuroscience 2025 meeting (SfN-2025), Jiangxi Kvvit Pharmaceutical showcased promising data on two drug candidates. KR232 is a next-generation treatment for schizophrenia, and KR233 has best-in-class potential for epilepsy. These presentations highlight Kvvit's growing pipeline focused on unmet needs in CNS disorders.
The SfN-2025 conference, a cornerstone global event for neuroscientists, provided an ideal platform to showcase these advancements to an audience of leading researchers, clinicians, and industry partners.
POSTER: KR232 – A Differentiated Antipsychotic Targeting Cognitive Symptoms
A Strategic Vision for CNS Therapeutics
The successful presentations of both KR233 and KR232 at a flagship conference like SfN-2025 marks Jiangxi Kvvit Pharmaceutical as an emerging innovator in the CNS space. The company has demonstrated a clear capability to identify critical therapeutic gaps and design sophisticated molecules to address them.
“Our dual focus on epilepsy and schizophrenia reflects our deep commitment to some of the most challenging areas in neuroscience,” said Dr. Shousheng Yan. “The positive reception from the scientific community at SfN-2025 validates our research strategy. We are actively advancing KR233 towards an FDA IND submission in Q1 2026 and are keen to further develop KR232 to meet the urgent need for better antipsychotics.”
With a pipeline bolstered by these promising candidates, Kvvit Pharma is poised to make significant contributions to the treatment of debilitating CNS disorders in the years to come.
Contact us:
Email: BDinfo@kryy.com.cn
